RAPT Therapeutics (RAPT) Retained Earnings: 2020-2024
Historic Retained Earnings for Therapeutics (RAPT) over the last 5 years, with Sep 2024 value amounting to -$561.3 million.
- Therapeutics' Retained Earnings fell 23.69% to -$561.3 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$561.3 million, marking a year-over-year decrease of 23.69%. This contributed to the annual value of -$484.7 million for FY2023, which is 31.75% down from last year.
- Latest data reveals that Therapeutics reported Retained Earnings of -$561.3 million as of Q3 2024, which was down 3.40% from -$542.9 million recorded in Q2 2024.
- Over the past 5 years, Therapeutics' Retained Earnings peaked at -$175.1 million during Q1 2020, and registered a low of -$561.3 million during Q3 2024.
- Moreover, its 3-year median value for Retained Earnings was -$422.4 million (2023), whereas its average is -$429.0 million.
- Data for Therapeutics' Retained Earnings shows a maximum YoY tumbled of 32.21% (in 2021) over the last 5 years.
- Quarterly analysis of 5 years shows Therapeutics' Retained Earnings stood at -$214.8 million in 2020, then crashed by 32.21% to -$284.0 million in 2021, then decreased by 29.52% to -$367.9 million in 2022, then slumped by 31.75% to -$484.7 million in 2023, then declined by 23.69% to -$561.3 million in 2024.
- Its Retained Earnings stands at -$561.3 million for Q3 2024, versus -$542.9 million for Q2 2024 and -$515.2 million for Q1 2024.